Skip to main content

Table 1 Demographics and quantification data in the training and validation sets; mean and range values are given

From: A novel genomic signature predicting FDG uptake in diverse metastatic tumors

  Training set (n = 71) Validation set (n = 13)
Age (years) 58 (28–80) 58 (36–77)
Females/males 40/31 9/4
LBM 52.3 (29.5–81.8) 47.9 (32.8–60.7)
Baseline blood glucose (mg/dl) 100.8 (66–149) 100.1 (78–126)
Injected dose (mCi) 11.5 (9.9–13.4) 11.3 (10,0–12.9)
PET quantification data
 Diameter of the lesion (cm) 6.4 (1.5–18.9) 8.1 (2.1–18.3)
 SUVmax 11.8 (3.7–31.3) 12.3 (2.7–21.7)
 SUVmed35 6.7 (2.4–16.7) 6.5 (2.0–10.7)
 SULa 4.8 (1.5–11) 5.1 (2.3–8.8)
 SUVglu 6.7 (2–14.9) 6.5 (2.1–11.5)
 MTV (cm3)a 45.2 (0.7–434) 197.4 (2.1–1009)
 TLGa 358.7 (2.3–3958.1) 1784 (4.1–9058.1)
 T/B 9.5 (1.4–35.8) 10.9 (2.5–26.8)
  1. Abbreviations: LBM lean body mass, SUVmax maximum standard uptake value, SUVmed35 thresholded 35% medium standard uptake value, SUVglu standard uptake value corrected for plasma glucose levels, SUL standard uptake value normalized by lean body mass, MTV metabolic tumor value, TLG total lesion glycolysis, T/B tumor-to-background ratio
  2. aMissing data: 3 in the training set and 1 in the validation set